GEN Exclusives

More »

GEN News Highlights

Back to Item »

Ortho-McNeil-Janssen Taps Anchor for Pepducin Technology

Deal includes Anchor’s preclinical gpr39-targeting program and $480 million in milestones.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

NIH Budget Woes

Do you think that budget problems are going to lead to a growing exodus of talented researchers and administrators from the NIH?

More »